BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:UCSF Dermatology Grand Rounds - 12 June 2024
X-WR-TIMEZONE:Pacific Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20260819T202940Z
UID:tag:localist.com\,2008:EventInstance_45995354424804
DTSTART:20240612T151000Z
DTEND:20240612T171500Z
DESCRIPTION:GRAND ROUNDS \nZoom\nFellow Expert Talks \n\nPatient Viewing Ca
 ncelled\n\nMohs Micrographic Surgery for Melanoma\n\nPartik Singh\, MD\, M
 BA\, Micrographic Surgery and Dermatologic Oncology Fellow\, UCSF \n\nObje
 ctives:\n\nUnderstand melanoma patient selection for Mohs surgery or excis
 ional surgery\n\nDiscuss pre/postoperative considerations for Mohs surgery
  for melanoma\n\nIllustrate surgical technique for staging/treatment of me
 lanoma with Mohs surgery\n\n \n\nThe Grey Zone: Tools to Navigate Surgical
  Uncertainty\n\nDivya Seth\, MD\, MPH\, Micrographic Surgery and Dermatolo
 gic Oncology Fellow\, UCSF\n\n \n\nObjectives:\n\nCan we define clinical a
 nd surgical uncertainty?\n\nCase 1: approaches for large and ill defined t
 umors\n\nCase 2: implementing guidelines and more for high grade SCC\n\n \
 n\nSuperficial radiation therapy as a standalone treatment for skin cancer
 s: What dermatologists need to know\n\nAyan Kusari\, MD\, Micrographic Sur
 gery and Dermatologic Oncology Fellow\, UCSF\n\nObjectives:\n\nExplain how
  SRT works and its effectiveness in treating various types of skin cancers
  compared to other treatment modalities.\n\nDiscuss the clinical guideline
 s and criteria for selecting patients who would benefit most from SRT as a
  standalone treatment.\n\nAnalyze potential adverse effects of SRT\, inclu
 ding long-term outcomes and patient quality of life considerations.\n\n \n
 \nA Review of Cutaneous Mucormycosis\n\nSarah Pourakbar\, MD\, Complex Med
 ical Dermatology Fellow\, UCSF\n\nObjectives:\n\nReview epidemiology\, ris
 k factors\, and clinical features of cutaneous mucormycosis for early reco
 gnition and initiation of treatment.\n\nDiscuss practice gaps in the curre
 nt guidelines for medical and surgical management of cutaneous mucormycosi
 s and review future directions for improved outcomes.\n\n \n\nSpeaker Disc
 losures: Partik Singh\, MD\, MBA\, Divya Seth\, MD\, MPH\, Ayan Kusari\, M
 D\, Sarah Pourakbar\, MD have all stated that they have no financial relat
 ionships to disclose.\n\nPlanner Disclosures:\nIlona Frieden\, MD has disc
 losed that she is a consultant for Venthera Bridgebio\, Data Safety Monito
 ring Advisory Board for Pfizer\, and Data Reviewer on the NCT02913612 Pedi
 atric Trials\nNetwork-NIH Efficacy\, Safety and Pharmacokinetics of Topica
 l Timolol in Infants With Infantile Hemangioma (IH) (TIM01).\nKelly Cordor
 o\, MD\, Hunter Shain\, PhD and Amanda Twigg\, MD have stated they have no
  relationships to disclose.
LOCATION:
SUMMARY:UCSF Dermatology Grand Rounds - 12 June 2024
URL;VALUE=URI:https://calendar.ucsf.edu/event/copy-of-ucsf-dermatology-gran
 d-rounds-15-may-2024-8493
END:VEVENT
END:VCALENDAR